Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series

Abstract

The efficacy and potential toxicity of rechallenge with combination ipilimumab and nivolumab has not been described. Retreatment of patients with immune checkpoint inhibitors in the setting of prior significant toxicity lacks evidence-based guidance.